Unknown

Dataset Information

0

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.


ABSTRACT: This study compared the clinical efficacy and safety of attention-deficit/hyperactivity disorder (ADHD) pharmacotherapy in children and adolescents 6-17 years of age. A systematic literature review was conducted to identify randomized controlled trials (RCTs) of pharmacologic monotherapies among children and adolescents with ADHD. A Bayesian network meta-analysis was conducted to compare change in symptoms using the ADHD Rating Scale Version IV (ADHD-RS-IV), Clinical Global Impression-Improvement (CGI-I) response, all-cause discontinuation, and adverse event-related discontinuation. Thirty-six RCTs were included in the analysis. The mean (95% credible interval [CrI]) ADHD-RS-IV total score change from baseline (active minus placebo) was -14.98 (-17.14, -12.80) for lisdexamfetamine dimesylate (LDX), -9.33 (-11.63, -7.04) for methylphenidate (MPH) extended release, -8.68 (-10.63, -6.72) for guanfacine extended release (GXR), and -6.88 (-8.22, -5.49) for atomoxetine (ATX); data were unavailable for MPH immediate release. The relative risk (95% CrI) for CGI-I response (active versus placebo) was 2.56 (2.21, 2.91) for LDX, 2.13 (1.70, 2.54) for MPH extended release, 1.94 (1.59, 2.29) for GXR, 1.77 (1.31, 2.26) for ATX, and 1.62 (1.05, 2.17) for MPH immediate release. Among non-stimulant pharmacotherapies, GXR was more effective than ATX when comparing ADHD-RS-IV total score change (with a posterior probability of 93.91%) and CGI-I response (posterior probability 76.13%). This study found that LDX had greater efficacy than GXR, ATX, and MPH in the treatment of children and adolescents with ADHD. GXR had a high posterior probability of being more efficacious than ATX, although their CrIs overlapped.

SUBMITTER: Joseph A 

PROVIDER: S-EPMC5532417 | BioStudies | 2017-01-01

REPOSITORIES: biostudies

Similar Datasets

2014-01-01 | S-EPMC4221603 | BioStudies
2020-01-01 | S-EPMC7376623 | BioStudies
2013-01-01 | S-EPMC3835923 | BioStudies
2016-01-01 | S-EPMC4863687 | BioStudies
2017-01-01 | S-EPMC5694170 | BioStudies
1000-01-01 | S-EPMC3824845 | BioStudies
2014-01-01 | S-EPMC4219557 | BioStudies
2011-01-01 | S-EPMC3225298 | BioStudies
2018-01-01 | S-EPMC5773633 | BioStudies
2015-01-01 | S-EPMC4425805 | BioStudies